Exane Asset Management Vertex Pharmaceuticals Inc Transaction History

Exane Asset Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 19, 2021	SELL	$181.39 - $202.99 $37.4 Million - $41.8 Million	-206,160 Closed	0 $0
Q2 2021 Jul 16, 2021	BUY	$187.49 - $221.1 $9.54 Million - $11.3 Million	50,908 Added 32.79%	206,160 $41.6 Million
Q1 2021 Apr 21, 2021	BUY	$207.02 - $241.31 $32.1 Million - $37.5 Million	155,252 New	155,252 $33.4 Million
Q1 2018 Apr 30, 2018	SELL	$151.6 - $177.13 $197,080 - $230,269	-1,300 Closed	0 $0
Q4 2017 Feb 08, 2018	BUY	$137.28 - $155.55 $54,500 - $61,753	397 Added 43.96%	1,300 $0
Q3 2017 Oct 13, 2017	BUY	$148.13 - $162.24 $133,761 - $146,502	903	903 $137 Million

1,724

221M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

Stay updated on Exane Asset Management with notifications on news.